We are analyzing https://link.springer.com/article/10.1186/1471-2407-10-530.

Title:
Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma | BMC Cancer
Description:
Background Multiple carcinogenesis is one of the major characteristics of human hepatocellular carcinoma (HCC). The history of multiple tumors, that is, whether they derive from a common precancerous or cancerous ancestor or individually from hepatocytes, is a major clinical issue. Multiple HCC is clinically classified as either intratumor metastasis (IM) or multicentric carcinogenesis (MC). Molecular markers that differentiate IM and MC are of interest to clinical practitioners because the clinical diagnoses of IM and MC often lead to different therapies. Methods We analyzed 30 multiple tumors from 15 patients for somatic mutations of cancer-related genes, chromosomal aberrations, and promoter methylation of tumor suppressor genes using techniques such as high-resolution melting, array-comparative genomic hybridization (CGH), and quantitative methylation-specific PCR. Results Somatic mutations were found in TP53 and CTNNB1 but not in CDKN2A or KRAS. Tumors from the same patient did not share the same mutations. Array-CGH analysis revealed variations in the number of chromosomal aberrations, and the detection of common aberrations in tumors from the same patient was found to depend on the total number of chromosomal aberrations. A promoter methylation analysis of genes revealed dense methylation in HCC but not in the adjacent non-tumor tissue. The correlation coefficients (r) of methylation patterns between tumors from the same patient were more similar than those between tumors from different patients. In total, 47% of tumor samples from the same patients had an r ≥ 0.8, whereas, in contrast, only 18% of tumor samples from different patients had an r ≥ 0.8 (p = 0.01). All IM cases were highly similar; that is, r ≥ 0.8 (p = 0.025). Conclusions The overall scarcity of common somatic mutations and chromosomal aberrations suggests that biological IM is likely to be rare. Tumors from the same patient had a methylation pattern that was more similar than those from different patients. As all clinical IM cases exhibited high similarity, the methylation pattern may be applicable to support the clinical diagnosis of IM and MC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

tumors, methylation, article, aberrations, multiple, hepatocellular, pubmed, google, scholar, cas, carcinoma, patients, common, cancer, hcc, analysis, chromosomal, genes, table, clinical, tumor, cases, somatic, mutations, patient, dna, genetic, data, human, carcinogenesis, molecular, genomic, file, figure, number, authors, patterns, similar, samples, additional, journal, multicentric, promoter, pcr, results, pattern, diagnosis, mutation, values, research,

Topics {✒️}

open access article array-comparative genomic hybridization organ-confined prostate adenocarcinoma single-nucleotide polymorphism arrays single-nucleotide polymorphism scanning multiple tumour nodules pre-publication history article download pdf comparative genomic hybridization human hepatocellular carcinoma uk/genetics/cgp/cosmic/ multicentric hepatocellular carcinoma high-resolution melting analysis recurrent hepatocellular carcinoma quantitative methylation-specific pcr full size image multiple hepatocellular carcinoma small hepatocellular carcinoma tumor-suppressor p53 gene privacy choices/manage cookies recurrent hepatocellular carcinomas functional liver reserve neoplastic liver cells primary liver cancer multiple hepatocellular carcinomas article taniguchi comparative lesion sequencing related subjects kikuya kato full access human molecular genetics recurrent metastatic nodules biomed central bmc cancer 10 high-resolution melting high-resolution melting [24] full size table cancer-related genes multiple genomic aberrations gene set included entire genomic sequencing cancer-specific methylation authors’ original file promoter methylation analysis european economic area salt lake city solid scientific basis polymerase chain reaction infrequent chromosomal aberrations chromosomal aberrations suggests

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma
         description:Multiple carcinogenesis is one of the major characteristics of human hepatocellular carcinoma (HCC). The history of multiple tumors, that is, whether they derive from a common precancerous or cancerous ancestor or individually from hepatocytes, is a major clinical issue. Multiple HCC is clinically classified as either intratumor metastasis (IM) or multicentric carcinogenesis (MC). Molecular markers that differentiate IM and MC are of interest to clinical practitioners because the clinical diagnoses of IM and MC often lead to different therapies. We analyzed 30 multiple tumors from 15 patients for somatic mutations of cancer-related genes, chromosomal aberrations, and promoter methylation of tumor suppressor genes using techniques such as high-resolution melting, array-comparative genomic hybridization (CGH), and quantitative methylation-specific PCR. Somatic mutations were found in TP53 and CTNNB1 but not in CDKN2A or KRAS. Tumors from the same patient did not share the same mutations. Array-CGH analysis revealed variations in the number of chromosomal aberrations, and the detection of common aberrations in tumors from the same patient was found to depend on the total number of chromosomal aberrations. A promoter methylation analysis of genes revealed dense methylation in HCC but not in the adjacent non-tumor tissue. The correlation coefficients (r) of methylation patterns between tumors from the same patient were more similar than those between tumors from different patients. In total, 47% of tumor samples from the same patients had an r ≥ 0.8, whereas, in contrast, only 18% of tumor samples from different patients had an r ≥ 0.8 (p = 0.01). All IM cases were highly similar; that is, r ≥ 0.8 (p = 0.025). The overall scarcity of common somatic mutations and chromosomal aberrations suggests that biological IM is likely to be rare. Tumors from the same patient had a methylation pattern that was more similar than those from different patients. As all clinical IM cases exhibited high similarity, the methylation pattern may be applicable to support the clinical diagnosis of IM and MC.
         datePublished:2010-10-06T00:00:00Z
         dateModified:2010-10-06T00:00:00Z
         pageStart:1
         pageEnd:8
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-10-530
         keywords:
            Somatic Mutation
            Promoter Methylation
            Chromosomal Aberration
            Multiple Tumor
            Multicentric Carcinogenesis
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig3_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kazuya Taniguchi
               affiliation:
                     name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                     address:
                        name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Terumasa Yamada
               affiliation:
                     name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                     address:
                        name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yo Sasaki
               affiliation:
                     name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                     address:
                        name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kikuya Kato
               affiliation:
                     name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                     address:
                        name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma
      description:Multiple carcinogenesis is one of the major characteristics of human hepatocellular carcinoma (HCC). The history of multiple tumors, that is, whether they derive from a common precancerous or cancerous ancestor or individually from hepatocytes, is a major clinical issue. Multiple HCC is clinically classified as either intratumor metastasis (IM) or multicentric carcinogenesis (MC). Molecular markers that differentiate IM and MC are of interest to clinical practitioners because the clinical diagnoses of IM and MC often lead to different therapies. We analyzed 30 multiple tumors from 15 patients for somatic mutations of cancer-related genes, chromosomal aberrations, and promoter methylation of tumor suppressor genes using techniques such as high-resolution melting, array-comparative genomic hybridization (CGH), and quantitative methylation-specific PCR. Somatic mutations were found in TP53 and CTNNB1 but not in CDKN2A or KRAS. Tumors from the same patient did not share the same mutations. Array-CGH analysis revealed variations in the number of chromosomal aberrations, and the detection of common aberrations in tumors from the same patient was found to depend on the total number of chromosomal aberrations. A promoter methylation analysis of genes revealed dense methylation in HCC but not in the adjacent non-tumor tissue. The correlation coefficients (r) of methylation patterns between tumors from the same patient were more similar than those between tumors from different patients. In total, 47% of tumor samples from the same patients had an r ≥ 0.8, whereas, in contrast, only 18% of tumor samples from different patients had an r ≥ 0.8 (p = 0.01). All IM cases were highly similar; that is, r ≥ 0.8 (p = 0.025). The overall scarcity of common somatic mutations and chromosomal aberrations suggests that biological IM is likely to be rare. Tumors from the same patient had a methylation pattern that was more similar than those from different patients. As all clinical IM cases exhibited high similarity, the methylation pattern may be applicable to support the clinical diagnosis of IM and MC.
      datePublished:2010-10-06T00:00:00Z
      dateModified:2010-10-06T00:00:00Z
      pageStart:1
      pageEnd:8
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-10-530
      keywords:
         Somatic Mutation
         Promoter Methylation
         Chromosomal Aberration
         Multiple Tumor
         Multicentric Carcinogenesis
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-530/MediaObjects/12885_2009_Article_2329_Fig3_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kazuya Taniguchi
            affiliation:
                  name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                  address:
                     name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Terumasa Yamada
            affiliation:
                  name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                  address:
                     name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yo Sasaki
            affiliation:
                  name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                  address:
                     name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kikuya Kato
            affiliation:
                  name:Osaka Medical Center for Cancer and Cardiovascular Diseases
                  address:
                     name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:10
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Osaka Medical Center for Cancer and Cardiovascular Diseases
      address:
         name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
         type:PostalAddress
      name:Osaka Medical Center for Cancer and Cardiovascular Diseases
      address:
         name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
         type:PostalAddress
      name:Osaka Medical Center for Cancer and Cardiovascular Diseases
      address:
         name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
         type:PostalAddress
      name:Osaka Medical Center for Cancer and Cardiovascular Diseases
      address:
         name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kazuya Taniguchi
      affiliation:
            name:Osaka Medical Center for Cancer and Cardiovascular Diseases
            address:
               name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Terumasa Yamada
      affiliation:
            name:Osaka Medical Center for Cancer and Cardiovascular Diseases
            address:
               name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Yo Sasaki
      affiliation:
            name:Osaka Medical Center for Cancer and Cardiovascular Diseases
            address:
               name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Kikuya Kato
      affiliation:
            name:Osaka Medical Center for Cancer and Cardiovascular Diseases
            address:
               name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
      name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
      name:Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
      name:Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

External Links {🔗}(132)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.67s.

LINK . SPRINGER . COM {}